Soft Peri-implant Tissue Around Different Abutment Materials
NCT ID: NCT03459547
Last Updated: 2021-09-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
10 participants
INTERVENTIONAL
2021-09-06
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This work will focus on the role of myofibroblasts during the early phases of the healing process in peri-implant tissues around four different abutment materials.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Peri-implant Marginal Bone and Soft Tissue Conditions Around Single Laser-Lok Implants Placed in Regenerated Extraction Sockets and in Native Bone: A 2-years Results of RCT
NCT03686865
Laterally Rotated Flap for Soft Tissue Augmentation Around Maxillary Loaded Osseointegrated Dental Implant
NCT06206499
Histological Analysis of Peri-implant Soft Tissue
NCT06862505
Surface Decontamination in Treatment of Peri-Implantitis
NCT03114956
Influence of Keratinized Mucosa on Dental Implants With Mucositis
NCT04874467
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It seems that the soft tissue adhesion is influenced by the properties (abutment material and micro-topography) of the implant components that are placed in contact with the soft tissues. Abutment material was found to influence bleeding on probing (BoP) at peri-implant soft tissues, as well.
Since wound healing occurs in the presence of a biomaterial (i.e. a foreign body) at a critical region, positive or negative interferences of wound healing events with this biomaterial and adaptation of the soft tissue to this biomaterial have to be taken into consideration. Biocompatibility, soft tissue adhesion, plaque retention, mechanical behavior and esthetics are listed among the criteria of material abutment selection. Titanium remains the most reliable material given its mechanical resistance, biocompatibility, modification of surface increasing cell adhesion and plaque retention. However, in the case of increased esthetics demands, particularly for thin biotype, zirconia and ceramics aluminum abutments give better results with comparable technical and biological outcomes to titanium abutments.
Polyetheretherketone (PEEK) is a strong thermoplastic material produced from polyetheretherketone resin. Because of its high mechanical strength and durability, good electrical characteristics and outstanding resistance to hydrolysis, PEEK has been used extensively in aerospace, automotive, chemical, electronics, petroleum, and food and beverage industries. Recently, a medical-grade PEEK was developed. Medical-grade PEEK has the same physical properties as PEEK; however, PEEK-OPTIMA™ is also biocompatible, has high chemical resistance and resists several different sterilization methods. It is noteworthy to mention that PEEK has an elastic modulus similar to that of the bone preventing marginal bone loss in case of occlusal overload. Due to the aforementioned properties, PEEK has been used as abutment material.
Morphology of the abutment deserves considerations, as well. Some physiological soft-tissue recession can be seen in time around implant restorations when a divergent emergence profile (the most common) is chosen next to the soft tissue. Recently it has been shown how some gingival coronal migration can be seen with the use of tapered emergence profile abutments. In fact, by using these tapered abutments or an implant design with a tapered shape at the neck implant level (transmucosal level), not only soft tissue migration but also hard tissue migration could be achieved over time.
Healing of peri-implant mucosa is characterized by a rapid formation of vascular structures and recruitment of inflammatory cells followed by the maturation of a tissue that eventually establishes a firm barrier of supracrestal connective tissue and long junctional epithelium, which effectively prevents downgrowth of a bacterial biofilm. Angiogenesis as a critical part of wound healing is noticed to peak at 2 weeks with a decline over 10 weeks, while the recruitment of inflammatory cells (B cells and T cells) occur in clusters and decrease from 4 to 8 weeks of healing in connective tissue.
However, little is available on the very early response that might determine the histological organization of peri-implant soft tissues in general and in contact to different macroscopic and microscopically modified materials. Peri-implant soft tissues are part of the gingiva and oral mucosa and implant placement occurs through the creation of an wound. Myofibroblasts represent key players in the physiological reconstruction of connective tissue after injury and in generating the pathological tissue deformations that characterize fibrosis. They constitute a critical cellular source of type I collagen, which is essential during wound healing. Excessive contraction and overproduction of extracellular matrix, mainly collagen, by myofibroblasts can cause tissue fibrosis with formation of hypertrophic scar characterized by reducedtensile strength and disoriented collagen fibres. In full thickness skin wounds, myofibroblast differentiation starts approximately a week after wounding, and contraction peaks at 5-15 days postwounding, but in oral cavity, this step occurs earlier than in skin, given the shorter healing time of these tissues.
Therefore the aim of the present study was to evaluate the myofibroblast component of peri-implant mucosal tissues at different healing abutment materials (titanium gr4, titanium gr 5, zirconium and PEEK) 24 hours after placement.
MATERIALS AND METHODS Ethical aspect This protocol will be evaluated by the Ethical Committee of Sapienza University of Rome after Department approval. Each patient will be provided with a written informed consent.
Study design Biomolecular study of biopsies taken from the peri-implant soft tissue 24 hours after implant and healing abutment placement of four different materials (titanium gr4, titanium gr 5, zirconium and PEEK).
Operators, blindness and allocation Implants and abutments will be placed by a single operator, not involved in other functions during the study. A second operator, not involved in implant or abutment placement, will perform the biopsy. The laboratory operator will be blind of the allocation of biopsies. The type of abutment associated with each implant will be determined in a closed envelope that is going to be opened only when implant is placed. Patients will be informed about the type of implants and abutments used but not about the exact location of each one.
Sample characteristics A total of 10 patients recruited for implant treatment at the Dental clinic of Sapienza University of Rome will participate in the study following the fulfilment of the inclusion and exclusion criteria.
Inclusion criteria:
(I) Age ≥ 18 years (II) Absence of Systemic Diseases / Disorders (III) Smoking ≤ 5 cigarettes per day (IV) Periodontally healthy or treated (V) Full-mouth plaque score (FMPS) ≤ 15% at baseline (VI) Full-mouth bleeding score (FMBS) ≤ 15% at baseline (VII) Presence of edentulous space needing an all on four or all on six treatment with overdenture (VIII) Width of the keratinized gingiva ≥ 2 at the level of the crest
Exclusion criteria: (exclusion of risk / confounding factors):
(I) Pregnancy / lactation (II) Use of systemic antibiotics in the last 3 months (III) Use of systemic antibiotics as prophylaxis for endocarditis (IV) A chronically treated patient (i.e. 2 weeks or longer) with medicines known to affect periodontal tissues (e.g. phenytoin, calcium antagonists, cyclosporine, warfarin and non-steroidal anti-inflammatory drugs) the last month before starting the study (V) Radiotherapy in the neck-head region (VI) HIV, TB, hepatitis or other infectious diseases (VII) Abuse with drugs or alcohol (VIII) Smoked cigarettes\> 5 cigarettes per day (IX) Untreated periodontitis (X) FMPS\> 15% at baseline (XI) FMBS\> 15% at baseline (XII) Implants with peri-implant history (XIII) Width of keratinized tissue over crest \<2 mm (XIV) Need for bone reconstruction around implants to be inserted
Clinical treatment
The protocol will follow Tomasi et al 2014 with the modification of a baseline sample taken when incising for the preparation of the flap. Briefly, following local anesthesia, flap elevation and implant placement (Sweden and Martina SpA, Padova, Italy), a specially designed abutment of four different materials (tigran gr4, tigran gr 5, zirconium and PEEK) will be connected to each implant following a double -blinded allocation and flaps will be sutured. Patients will rinse with chlorhexidine for 1 weeks until suture removal. After 24 hours from implant placement, a custum-made cutting device will be used to retrieve a circumferential biopsy of the peri-implant soft tissue. A guide pin will be connected to the abutment and a circular punch with a cutting edge will be forced apically around the abutment dissected a 1.5 mm thick collar of peri-implant soft tissue and removing it together with the abutment and the cutting device. The whole system will be placed in 4% formalin and transferred to a 70% ethanol solution after 48 h.
Cito- histological analysis
Cell Immunofluorescent staining and confocal microscopy. Once harvested with a punch around the implant neck, cells are obtained using the explant method. The 2 mm samples are first minced and then placed in a culture flask and incubated in complete media in 5% CO2 at 37°C. Alternatively, samples are placed in high glucose DMEM supplemented with 15 % FBS and antibiotics, and stored at 4 C for 24 hrs. Cells are then fixed in 4% PFA in PBS for 30 min at room temperature. To label the molecules of interest, the cells are permeabilized in PBS/10% goat serum/0.3% Triton X-100 (1h, 20°C), followed by primary antibodies (against cytoskeletal/cytoskeleton associated proteins and matrix proteins) in PBS/0.1% BSA/0.3% Triton X-100 (4°C, 20°C), washed, and incubated with secondary antibody, DAPI and/or phalloidin (4°C, 20°C). Confocal fluorescence (Leica SP8) and epifluorescence microscopy (DeltaVision system) are performed using 20x/ 0.50 NA and 40x/ 0.80 NA objectives (Olympus FV1000).
Biopsy tissue microscopy. Tissue samples obtained after surgical removal are fixed in formalin and sectioned with a vibratome (Leica, VT100s) to obtain 200 μm thick slices. For optimized antibody penetration, sequential 24 h-incubation (4°C) are performed for each primary and secondary antibody incubation and washing steps (PBS/2% goat serum/0.1% Triton X-100/0.05% NaN3). Images are acquired using two-photon microscopy with a 20x /NA 0.95 objective (Olympus XLUMPlanFI 206) and excitation at 910/1090/1180 nm.
Statistical analysis
A total of 80 samples will be taken at implant insertion and 24 hours after , each analyzed three times. The results will be expressed as mean and SD values and ANOVA and Mann-Whitney test from appropriate software (STATA version 13.1; StataCorp LP; College Station, TX) used to find the difference among the four abutment materials
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
dental implant + PEEK (test)
Dental implant insertion, material polyetheretherketone
dental implant
Local anesthesia, flap preparation, dental implant insertion, flap suture, healing abutment insertion. Peri-implant soft tissue samples taken prior to implant placement and 24 hours after.
dental implant + Ti-5 (control)
Dental implant insertion, material titanium group 5
dental implant
Local anesthesia, flap preparation, dental implant insertion, flap suture, healing abutment insertion. Peri-implant soft tissue samples taken prior to implant placement and 24 hours after.
dental implant + zirconia (control)
dental implant insertion, material zirconia
dental implant
Local anesthesia, flap preparation, dental implant insertion, flap suture, healing abutment insertion. Peri-implant soft tissue samples taken prior to implant placement and 24 hours after.
dental implant + Ti-4 (control)
dental implant insertion, material titanium group 4
dental implant
Local anesthesia, flap preparation, dental implant insertion, flap suture, healing abutment insertion. Peri-implant soft tissue samples taken prior to implant placement and 24 hours after.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dental implant
Local anesthesia, flap preparation, dental implant insertion, flap suture, healing abutment insertion. Peri-implant soft tissue samples taken prior to implant placement and 24 hours after.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Absence of Systemic Diseases / Disorders
* Smoking ≤ 5 cigarettes per day
* Periodontally healthy or treated
* Full-mouth plaque score (FMPS) ≤ 15% at baseline
* Full-mouth bleeding score (FMBS) ≤ 15% at baseline
* Presence of edentulous space needing an all on four or all on six treatment with overdenture
* Width of the keratinized gingiva ≥ 2 at the level of the crest
Exclusion Criteria
* Use of systemic antibiotics in the last 3 months
* Use of systemic antibiotics as prophylaxis for endocarditis
* A chronically treated patient (i.e. 2 weeks or longer) with medicines known to affect periodontal tissues (e.g. phenytoin, calcium antagonists, cyclosporine, warfarin and non-steroidal anti-inflammatory drugs) the last month before starting the study
* Radiotherapy in the neck-head region
* HIV, TB, hepatitis or other infectious diseases
* Abuse with drugs or alcohol
* Smoked cigarettes\> 5 cigarettes per day
* Untreated periodontitis
* FMPS\> 15% at baseline
* FMBS\> 15% at baseline
* Implants with peri-implant history
* Width of keratinized tissue over crest \<2 mm
* Need for bone reconstruction around implants to be inserted
18 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Max-Planck Institute of Molecular Cell Biology and Genetics
OTHER
University of Roma La Sapienza
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andrea Pilloni MD DDS MS
MD DDS MS
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrea Pilloni, MD DDS Ms
Role: PRINCIPAL_INVESTIGATOR
University of Roma La Sapienza
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Oral and Maxillofacial Sciences. Section of Periodontics.Sapienza, University of Rome
Rome, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Lindhe J, Wennstrom JL & Berglundh T. The mucosa at teeth and implants. In: Lindhe, J., Lang, N. P. & Karring, T. (eds). Clinical Periodontology and Implant Dentistry, 5th edition, pp. 69-85, 2008.
Small PN, Tarnow DP. Gingival recession around implants: a 1-year longitudinal prospective study. Int J Oral Maxillofac Implants. 2000 Jul-Aug;15(4):527-32.
Apse P, Zarb GA, Schmitt A, Lewis DW. The longitudinal effectiveness of osseointegrated dental implants. The Toronto Study: peri-implant mucosal response. Int J Periodontics Restorative Dent. 1991;11(2):94-111. No abstract available.
Rodriguez X, Navajas A, Vela X, Fortuno A, Jimenez J, Nevins M. Arrangement of Peri-implant Connective Tissue Fibers Around Platform-Switching Implants with Conical Abutments and Its Relationship to the Underlying Bone: A Human Histologic Study. Int J Periodontics Restorative Dent. 2016 Jul-Aug;36(4):533-40. doi: 10.11607/prd.2580.
Cocchetto R, Canullo L. The "hybrid abutment": a new design for implant cemented restorations in the esthetic zones. Int J Esthet Dent. 2015 Summer;10(2):186-208.
Braun E, Iacono VJ. Tapered tips to think about. Int J Periodontics Restorative Dent. 2006 Feb;26(1):7. No abstract available.
Urdaneta RA, Leary J, Lubelski W, Emanuel KM, Chuang SK. The effect of implant size 5 x 8 mm on crestal bone levels around single-tooth implants. J Periodontol. 2012 Oct;83(10):1235-44. doi: 10.1902/jop.2012.110299. Epub 2012 Feb 6.
Schwarz F, Mihatovic I, Becker J, Bormann KH, Keeve PL, Friedmann A. Histological evaluation of different abutments in the posterior maxilla and mandible: an experimental study in humans. J Clin Periodontol. 2013 Aug;40(8):807-15. doi: 10.1111/jcpe.12115. Epub 2013 Jun 3.
Waerhaug J. Subgingival plaque and loss of attachment in periodontosis as evaluated on extracted teeth. J Periodontol. 1977 Mar;48(3):125-30. doi: 10.1902/jop.1977.48.3.125.
Welander M, Abrahamsson I, Berglundh T. The mucosal barrier at implant abutments of different materials. Clin Oral Implants Res. 2008 Jul;19(7):635-41. doi: 10.1111/j.1600-0501.2008.01543.x. Epub 2008 May 19.
Rompen E, Domken O, Degidi M, Pontes AE, Piattelli A. The effect of material characteristics, of surface topography and of implant components and connections on soft tissue integration: a literature review. Clin Oral Implants Res. 2006 Oct;17 Suppl 2:55-67. doi: 10.1111/j.1600-0501.2006.01367.x. No abstract available.
Sanz-Martin I, Sanz-Sanchez I, Carrillo de Albornoz A, Figuero E, Sanz M. Effects of modified abutment characteristics on peri-implant soft tissue health: A systematic review and meta-analysis. Clin Oral Implants Res. 2018 Jan;29(1):118-129. doi: 10.1111/clr.13097. Epub 2017 Oct 26.
Garcia B, Camacho F, Penarrocha D, Tallarico M, Perez S, Canullo L. Influence of plasma cleaning procedure on the interaction between soft tissue and abutments: a randomized controlled histologic study. Clin Oral Implants Res. 2017 Oct;28(10):1269-1277. doi: 10.1111/clr.12953. Epub 2016 Aug 23.
Tomasi C, Tessarolo F, Caola I, Wennstrom J, Nollo G, Berglundh T. Morphogenesis of peri-implant mucosa revisited: an experimental study in humans. Clin Oral Implants Res. 2014 Sep;25(9):997-1003. doi: 10.1111/clr.12223. Epub 2013 Jun 26.
Linkevicius T, Vaitelis J. The effect of zirconia or titanium as abutment material on soft peri-implant tissues: a systematic review and meta-analysis. Clin Oral Implants Res. 2015 Sep;26 Suppl 11:139-47. doi: 10.1111/clr.12631. Epub 2015 Jun 13.
Sailer I, Philipp A, Zembic A, Pjetursson BE, Hammerle CH, Zwahlen M. A systematic review of the performance of ceramic and metal implant abutments supporting fixed implant reconstructions. Clin Oral Implants Res. 2009 Sep;20 Suppl 4:4-31. doi: 10.1111/j.1600-0501.2009.01787.x.
Neumann EA, Villar CC, Franca FM. Fracture resistance of abutment screws made of titanium, polyetheretherketone, and carbon fiber-reinforced polyetheretherketone. Braz Oral Res. 2014;28:S1806-83242014000100239. doi: 10.1590/1807-3107bor-2014.vol28.0028. Epub 2014 Aug 4.
Steinberg EL, Rath E, Shlaifer A, Chechik O, Maman E, Salai M. Carbon fiber reinforced PEEK Optima--a composite material biomechanical properties and wear/debris characteristics of CF-PEEK composites for orthopedic trauma implants. J Mech Behav Biomed Mater. 2013 Jan;17:221-8. doi: 10.1016/j.jmbbm.2012.09.013. Epub 2012 Oct 11.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0000102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.